publication date: Sep. 22, 2016

NCI CTEP-Approved Trials for the Month of August

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies for August.  For further information, contact the principal investigator listed.

Phase I

9914: A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors. National Cancer Institute LAO; Thomas, Anish. (301) 451-8418

9952: Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC). Mayo Clinic Cancer Center LAO; Mohindra, Pranshu. (410) 328-6080

Phase II

A021501: Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas. Alliance for Clinical Trials in Oncology; Katz, Matthew Harold G. (713) 794-4660

S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. SWOG; Rodler, Eve Therese. (916) 734-5959

S1507: A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies. SWOG; Gadgeel, Shirish M. (313) 576-8753

Phase III

A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients … Continue reading CCL 39-08 NCI CTEP-Approved Trials for the Months of August and September

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.